Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsCancer

PUBLISHER: Grand View Research | PRODUCT CODE: 1433626

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1433626

Circulating Tumor Cells Market Size, Share & Trends Analysis Report By Application (Clinical/Liquid Biopsy, Research), By Specimen (Bone Marrow, Blood), By Product, By Technology, By End-use, By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Circulating Tumor Cells Market Growth & Trends:

The global circulating tumor cells market size is anticipated to reach USD 27.55 billion by 2030, expanding at a CAGR of 13.62% from 2024 to 2030, according to a new report by Grand View Research, Inc. This is attributed to rising prevalence of cancer worldwide, increasing demand for non-invasive cancer diagnostic tools, and advancements in circulating tumor cells (CTC) technologies.

In recent years, CTCs are increasingly used for determining the prognosis of cancer and helping clinicians decide the type of therapy required for cancer treatment. CTCs have wide applications in several areas of cancer management-early detection of cancer, risk assessment of cancer recurrence, guidance for therapies, and continuous monitoring of a patient during cancer treatment. The development of various tumor markers utilizing CTCs, which can be used to diagnose or monitor cancer, is expected to boost the adoption of CTCs over the forecast period. Therefore, it can be concluded that the detection of CTCs in the peripheral blood of patients with cancer acts as a promising diagnostic tool. For instance, quantitation and genomic profiling of CTCs enables cost-effective & accurate noninvasive monitoring of prostate cancer. The detection of CTCs is predictive for survival of cancer patients.

The limited applicability of these cells in rare cancers has hampered revenue growth to a certain extent. Circulating tumor cells are not applicable to tumors characterized by EpCAM negativity or low expression, such as neurogenic cancers. For instance, there is negligible evidence for the characterization of circulating tumor cells for sarcoma. Conversely, numerous methods are being studied for the isolation of these cells, which include methods based on epithelial antigen-targeted antibodies, anticipating to overcome these challenges in the near future.

However, in recent years, there has been a push for practical application, largely as a result of a wave of large players centralizing the technology through acquisitions and numerous partnerships with pharmaceutical firms to advance the formation of a value chain and speed up the CTC market's growth. For instance, in June 2023, to develop a novel test for the detection of tumor cells that metastatic cancers shed into the blood, the University of Washington School of Medicine collaborated with RareCyte, Inc., which is a biotech company headquartered in Seattle. In addition, according to the research, the understanding of the circulating tumor cells in the bloodstream can track the changes in tumor cells, thus optimizing the treatment.

Circulating Tumor Cells Market Report Highlights:

  • Based on technology, CTC detection & enrichment methods dominated the market in 2023 with a revenue share of 66.2% owing to the increased availability of products for CTC enrichment and isolation as well as high usage and product penetration across the globe
  • The CTC analysis segment is expected to grow at the fastest CAGR from 2024 to 2030 due to the growing application potential of CTC analysis for investigational research, drug development, and biomarker studies
  • Based on application, the research segment dominated the market in 2023 and it is expected to witness the fastest CAGR from 2024 to 2030
  • Kits & reagent dominated the product segment in 2023, and it is expected to witness the fastest growth in forecast period of 2024-2030
  • Based on specimen, the blood segment dominated the market in 2023. The other body fluids segment is expected to witness the fastest CAGR from 2024 to 2030
  • Based on end-use, the research & academic institutes segment dominated the market in 2023 due to increasing focus on research and development activities for cancer diagnosis and treatment
  • North America dominated the CTC market in 2023, owing to factors such as the presence of key market players Bio-Techne Corporation, Precision Medicine Group LLC, Epic Sciences, APPLIED DNA SCIENCES, INC., and LungLife AI, Inc. and the growth in pharmaceutical & biotechnology research sectors in this region
  • Asia Pacific is expected to register the fastest CAGR over the forecast period due to several companies expanding their presence in countries like Japan
Show more
Product Code: 978-1-68038-287-7

Table of Contents

Chapter 1. Circulating Tumor Cells Market: Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Application
    • 1.2.3. Product
    • 1.2.4. Specimen
    • 1.2.5. End-use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Circulating Tumor Cells Market: Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights

Chapter 3. Circulating Tumor Cells Market: Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Advancements in chip technology
      • 3.2.1.2. Expanding applications of CTCs
      • 3.2.1.3. Growing demand for early and rapid cancer diagnosis
      • 3.2.1.4. Growing incidence of cancer
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Consistency-related challenges in CTC detection and enrichment
      • 3.2.2.2. Higher preference for Point-of-Care (POC) testing and nonavailability of POC adaptable CTC tests
      • 3.2.2.3. Lower applicability of CTCs in rare cancers
  • 3.3. Circulating Tumor Cells Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Circulating Tumor Cells Market: Technology Estimates & Trend Analysis

  • 4.1. Technology Market Share, 2023 & 2030
  • 4.2. Global Circulating Tumor Cells Market by Technology Outlook
  • 4.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.3.1. CTC Detection & Enrichment Methods
      • 4.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.2. Immunocapture (Label-based)
      • 4.3.1.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.2.2. Positive Selection
      • 4.3.1.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.2.3. Negative Selection
      • 4.3.1.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.3. Size-based Separation (Label-free)
      • 4.3.1.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.3.2. Membrane-based
      • 4.3.1.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.3.3. Microfluidic-based
      • 4.3.1.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.4. Density-based Separation (Label-free)
      • 4.3.1.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.5. Combined Methods
      • 4.3.1.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. CTC Direct Detection Methods
      • 4.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.2. SERS
      • 4.3.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.3. Microscopy
      • 4.3.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.4. Others
      • 4.3.2.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. CTC Analysis
      • 4.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Circulating Tumor Cells Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2023 & 2030
  • 5.2. Global Circulating Tumor Cells Market by Application Outlook
  • 5.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.3.1. Clinical/ Liquid Biopsy
      • 5.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.3.1.2. Risk Assessment
      • 5.3.1.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.3.1.3. Screening and Monitoring
      • 5.3.1.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. Research
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.3.2.2. Cancer Stem Cell & Tumorogenesis Research
      • 5.3.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.3.2.3. Drug/Therapy Development
      • 5.3.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Circulating Tumor Cells Market: Product Estimates & Trend Analysis

  • 6.1. Product Market Share, 2023 & 2030
  • 6.2. Global Circulating Tumor Cells Market by Product Outlook
  • 6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.3.1. Kits & reagents
      • 6.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. Blood collection tubes
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Devices or systems
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Circulating Tumor Cells Market: Specimen Estimates & Trend Analysis

  • 7.1. Specimen Market Share, 2023 & 2030
  • 7.2. Global Circulating Tumor Cells Market by Specimen Outlook
  • 7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.3.1. Blood
      • 7.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. Bone marrow
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Other body fluids
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Circulating Tumor Cells Market: End-use Estimates & Trend Analysis

  • 8.1. End-use Market Share, 2023 & 2030
  • 8.2. Global Circulating Tumor Cells Market by End-use Outlook
  • 8.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 8.3.1. Research and academic institutes
      • 8.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. Hospital and clinics
      • 8.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Diagnostic centers
      • 8.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Circulating Tumor Cells Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Share Analysis, 2023 & 2030
  • 9.2. North America
    • 9.2.1. North America market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.2.2. U.S.
      • 9.2.2.1. Key country dynamics
      • 9.2.2.2. Regulatory framework
      • 9.2.2.3. Competitive scenario
      • 9.2.2.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.2.2.5. Target disease prevalence
    • 9.2.3. Canada
      • 9.2.3.1. Key country dynamics
      • 9.2.3.2. Regulatory framework
      • 9.2.3.3. Competitive scenario
      • 9.2.3.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.2.3.5. Target disease prevalence
  • 9.3. Europe
    • 9.3.1. Europe market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.2. UK
      • 9.3.2.1. Key country dynamics
      • 9.3.2.2. Regulatory framework
      • 9.3.2.3. Competitive scenario
      • 9.3.2.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.3.2.5. Target disease prevalence
    • 9.3.3. Germany
      • 9.3.3.1. Key country dynamics
      • 9.3.3.2. Regulatory framework
      • 9.3.3.3. Competitive scenario
      • 9.3.3.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.3.3.5. Target disease prevalence
    • 9.3.4. France
      • 9.3.4.1. Key country dynamics
      • 9.3.4.2. Regulatory framework
      • 9.3.4.3. Competitive scenario
      • 9.3.4.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.3.4.5. Target disease prevalence
    • 9.3.5. Italy
      • 9.3.5.1. Key country dynamics
      • 9.3.5.2. Regulatory framework
      • 9.3.5.3. Competitive scenario
      • 9.3.5.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.3.5.5. Target disease prevalence
    • 9.3.6. Spain
      • 9.3.6.1. Key country dynamics
      • 9.3.6.2. Regulatory framework
      • 9.3.6.3. Competitive scenario
      • 9.3.6.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.3.6.5. Target disease prevalence
    • 9.3.7. Norway
      • 9.3.7.1. Key country dynamics
      • 9.3.7.2. Regulatory framework
      • 9.3.7.3. Competitive scenario
      • 9.3.7.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.3.7.5. Target disease prevalence
    • 9.3.8. Sweden
      • 9.3.8.1. Key country dynamics
      • 9.3.8.2. Regulatory framework
      • 9.3.8.3. Competitive scenario
      • 9.3.8.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.3.8.5. Target disease prevalence
    • 9.3.9. Denmark
      • 9.3.9.1. Key country dynamics
      • 9.3.9.2. Regulatory framework
      • 9.3.9.3. Competitive scenario
      • 9.3.9.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.3.9.5. Target disease prevalence
  • 9.4. Asia Pacific
    • 9.4.1. Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.2. Japan
      • 9.4.2.1. Key country dynamics
      • 9.4.2.2. Regulatory framework
      • 9.4.2.3. Competitive scenario
      • 9.4.2.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.4.2.5. Target disease prevalence
    • 9.4.3. China
      • 9.4.3.1. Key country dynamics
      • 9.4.3.2. Regulatory framework
      • 9.4.3.3. Competitive scenario
      • 9.4.3.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.4.3.5. Target disease prevalence
    • 9.4.4. India
      • 9.4.4.1. Key country dynamics
      • 9.4.4.2. Regulatory framework
      • 9.4.4.3. Competitive scenario
      • 9.4.4.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.4.4.5. Target disease prevalence
    • 9.4.5. Australia
      • 9.4.5.1. Key country dynamics
      • 9.4.5.2. Regulatory framework
      • 9.4.5.3. Competitive scenario
      • 9.4.5.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.4.5.5. Target disease prevalence
    • 9.4.6. South Korea
      • 9.4.6.1. Key country dynamics
      • 9.4.6.2. Regulatory framework
      • 9.4.6.3. Competitive scenario
      • 9.4.6.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.4.6.5. Target disease prevalence
    • 9.4.7. Thailand
      • 9.4.7.1. Key country dynamics
      • 9.4.7.2. Regulatory framework
      • 9.4.7.3. Competitive scenario
      • 9.4.7.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.4.7.5. Target disease prevalence
  • 9.5. Latin America
    • 9.5.1. Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.2. Brazil
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Regulatory framework
      • 9.5.2.3. Competitive scenario
      • 9.5.2.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.5.2.5. Target disease prevalence
    • 9.5.3. Mexico
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. Regulatory framework
      • 9.5.3.3. Competitive scenario
      • 9.5.3.4. Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.5.3.5. Target disease prevalence
    • 9.5.4. Argentina
      • 9.5.4.1. Key country dynamics
      • 9.5.4.2. Regulatory framework
      • 9.5.4.3. Competitive scenario
      • 9.5.4.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.5.4.5. Target disease prevalence
  • 9.6. MEA
    • 9.6.1. MEA market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.6.2. South Africa
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Regulatory framework
      • 9.6.2.3. Competitive scenario
      • 9.6.2.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.6.2.5. Target disease prevalence
    • 9.6.3. Saudi Arabia
      • 9.6.3.1. Key country dynamics
      • 9.6.3.2. Regulatory framework
      • 9.6.3.3. Competitive scenario
      • 9.6.3.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.6.3.5. Target disease prevalence
    • 9.6.4. UAE
      • 9.6.4.1. Key country dynamics
      • 9.6.4.2. Regulatory framework
      • 9.6.4.3. Competitive scenario
      • 9.6.4.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.6.4.5. Target disease prevalence
    • 9.6.5. Kuwait
      • 9.6.5.1. Key country dynamics
      • 9.6.5.2. Regulatory framework
      • 9.6.5.3. Competitive scenario
      • 9.6.5.4. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.6.5.5. Target disease prevalence

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2. Company/Competition Categorization
  • 10.3. Vendor Landscape
    • 10.3.1. List of key distributors and channel partners
    • 10.3.2. Key customers
    • 10.3.3. Key company position analysis, 2023
  • 10.4. Company Profiles
    • 10.4.1. QIAGEN
      • 10.4.1.1. Company overview
      • 10.4.1.2. Financial performance
      • 10.4.1.3. Product benchmarking
      • 10.4.1.4. Strategic initiatives
    • 10.4.2. Bio-Techne Corp.
      • 10.4.2.1. Company overview
      • 10.4.2.2. Financial performance
      • 10.4.2.3. Product benchmarking
      • 10.4.2.4. Strategic initiatives
    • 10.4.3. Precision for Medicine
      • 10.4.3.1. Company overview
      • 10.4.3.2. Financial performance
      • 10.4.3.3. Product benchmarking
      • 10.4.3.4. Strategic initiatives
    • 10.4.4. AVIVA Biosciences
      • 10.4.4.1. Company overview
      • 10.4.4.2. Financial performance
      • 10.4.4.3. Product benchmarking
      • 10.4.4.4. Strategic initiatives
    • 10.4.5. BIOCEPT, Inc.
      • 10.4.5.1. Company overview
      • 10.4.5.2. Financial performance
      • 10.4.5.3. Product benchmarking
      • 10.4.5.4. Strategic initiatives
    • 10.4.6. BioCEP Ltd.
      • 10.4.6.1. Company overview
      • 10.4.6.2. Financial performance
      • 10.4.6.3. Product benchmarking
      • 10.4.6.4. Strategic initiatives
    • 10.4.7. Fluxion Biosciences, Inc.
      • 10.4.7.1. Company overview
      • 10.4.7.2. Financial performance
      • 10.4.7.3. Product benchmarking
      • 10.4.7.4. Strategic initiatives
    • 10.4.8. Greiner Bio-One International GmbH
      • 10.4.8.1. Company overview
      • 10.4.8.2. Financial performance
      • 10.4.8.3. Product benchmarking
      • 10.4.8.4. Strategic initiatives
    • 10.4.9. Ikonisys, Inc.
      • 10.4.9.1. Company overview
      • 10.4.9.2. Financial performance
      • 10.4.9.3. Product benchmarking
      • 10.4.9.4. Strategic initiatives
    • 10.4.10. Miltenyi Biotec
      • 10.4.10.1. Company overview
      • 10.4.10.2. Financial performance
      • 10.4.10.3. Product benchmarking
      • 10.4.10.4. Strategic initiatives
    • 10.4.11. IVDiagnostics
      • 10.4.11.1. Company overview
      • 10.4.11.2. Financial performance
      • 10.4.11.3. Product benchmarking
      • 10.4.11.4. Strategic initiatives
    • 10.4.12. BioFluidica
      • 10.4.12.1. Company overview
      • 10.4.12.2. Financial performance
      • 10.4.12.3. Product benchmarking
      • 10.4.12.4. Strategic initiatives
    • 10.4.13. Canopus Bioscience Ltd.
      • 10.4.13.1. Company overview
      • 10.4.13.2. Financial performance
      • 10.4.13.3. Product benchmarking
      • 10.4.13.4. Strategic initiatives
    • 10.4.14. Biolidics Limited
      • 10.4.14.1. Company overview
      • 10.4.14.2. Financial performance
      • 10.4.14.3. Product benchmarking
      • 10.4.14.4. Strategic initiatives
    • 10.4.15. Creativ MicroTech , Inc.
      • 10.4.15.1. Company overview
      • 10.4.15.2. Financial performance
      • 10.4.15.3. Product benchmarking
      • 10.4.15.4. Strategic initiatives
    • 10.4.16. LungLife AI
      • 10.4.16.1. Company overview
      • 10.4.16.2. Financial performance
      • 10.4.16.3. Product benchmarking
      • 10.4.16.4. Strategic initiatives
    • 10.4.17. Epic Sciences
      • 10.4.17.1. Company overview
      • 10.4.17.2. Financial performance
      • 10.4.17.3. Product benchmarking
      • 10.4.17.4. Strategic initiatives
    • 10.4.18. Rarecells Diagnostics
      • 10.4.18.1. Company overview
      • 10.4.18.2. Financial performance
      • 10.4.18.3. Product benchmarking
      • 10.4.18.4. Strategic initiatives
    • 10.4.19. ScreenCell
      • 10.4.19.1. Company overview
      • 10.4.19.2. Financial performance
      • 10.4.19.3. Product benchmarking
      • 10.4.19.4. Strategic initiatives
    • 10.4.20. Menarini Silicon Biosystems
      • 10.4.20.1. Company overview
      • 10.4.20.2. Financial performance
      • 10.4.20.3. Product benchmarking
      • 10.4.20.4. Strategic initiatives
    • 10.4.21. LineaRx, Inc. (Vitatex, Inc.)
      • 10.4.21.1. Company overview
      • 10.4.21.2. Financial performance
      • 10.4.21.3. Product benchmarking
      • 10.4.21.4. Strategic initiatives
    • 10.4.22. Sysmex Corporation
      • 10.4.22.1. Company overview
      • 10.4.22.2. Financial performance
      • 10.4.22.3. Product benchmarking
      • 10.4.22.4. Strategic initiatives
    • 10.4.23. STEMCELL Technologies, Inc.
      • 10.4.23.1. Company overview
      • 10.4.23.2. Financial performance
      • 10.4.23.3. Product benchmarking
      • 10.4.23.4. Strategic initiatives
Show more
Product Code: 978-1-68038-287-7

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America circulating tumor cells market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 4 North America circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 5 North America circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 6 North America circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 7 North America circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 U.S. circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 9 U.S. circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 10 U.S. circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 11 U.S. circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 12 U.S. circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 13 Canada circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 14 Canada circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 15 Canada circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 16 Canada circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 17 Canada circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 18 Europe circulating tumor cells market, by region, 2018 - 2030 (USD Million)
  • Table 19 Europe circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 20 Europe circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 21 Europe circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 22 Europe circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 23 Europe circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 UK circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 25 UK circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 26 UK circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 27 UK circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 28 UK circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 29 Germany circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 30 Germany circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 31 Germany circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 32 Germany circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 33 Germany circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Italy circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 35 Italy circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 36 Italy circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 37 Italy circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 38 Italy circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 39 France circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 40 France circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 41 France circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 42 France circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 43 France circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 44 Spain circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 45 Spain circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 46 Spain circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 47 Spain circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 48 Spain circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 49 Sweden circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 50 Sweden circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 51 Sweden circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 52 Sweden circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 53 Sweden circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 54 Denmark circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 55 Denmark circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 56 Denmark circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 57 Denmark circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 58 Denmark circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Norway circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 60 Norway circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 61 Norway circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 62 Norway circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 63 Norway circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific circulating tumor cells market, by region, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 67 Asia Pacific circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 68 Asia Pacific circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 69 Asia Pacific circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 70 China circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 71 China circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 72 China circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 73 China circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 74 China circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 75 Japan circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 76 Japan circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 77 Japan circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 78 Japan circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 79 Japan circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 80 India circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 81 India circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 82 India circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 83 India circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 84 India circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 85 South Korea circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 86 South Korea circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 87 South Korea circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 88 South Korea circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 89 South Korea circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 90 Australia circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 91 Australia circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 92 Australia circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 93 Australia circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 94 Australia circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 95 Thailand circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 96 Thailand circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 97 Thailand circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 98 Thailand circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 99 Thailand circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 100 Latin America circulating tumor cells market, by region, 2018 - 2030 (USD Million)
  • Table 101 Latin America circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 102 Latin America circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 103 Latin America circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 104 Latin America circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 105 Latin America circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 106 Brazil circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 107 Brazil circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 108 Brazill circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 109 Brazil circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 110 Brazil circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 111 Mexico circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 112 Mexico circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 113 Mexico circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 114 Mexico circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 115 Mexico circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 116 Argentina circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 117 Argentina circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 118 Argentina circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 119 Argentina circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 120 Argentina circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 121 Middle East & Africa circulating tumor cells market, by region, 2018 - 2030 (USD Million)
  • Table 122 Middle East & Africa circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 123 Middle East & Africa circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 124 Middle East & Africa circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 125 Middle East & Africa circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 126 Middle East & Africa circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 127 South Africa circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 128 South Africa circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 129 South Africa circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 130 South Africa circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 131 South Africa circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 132 Saudi Arabia circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 133 Saudi Arabia circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 134 Saudi Arabia circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 135 Saudi Arabia circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 136 Saudi Arabia circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 137 UAE circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 138 UAE circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 139 UAE circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 140 UAE circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 141 UAE circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)
  • Table 142 Kuwait circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
  • Table 143 Kuwait circulating tumor cells market, by application, 2018 - 2030 (USD Million)
  • Table 144 Kuwait circulating tumor cells market, by product, 2018 - 2030 (USD Million)
  • Table 145 Kuwait circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
  • Table 146 Kuwait circulating tumor cells market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Circulating tumor cells market: market outlook
  • Fig. 9 Circulating tumor cells competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Circulating tumor cells market driver impact
  • Fig. 15 Circulating tumor cells market restraint impact
  • Fig. 16 Circulating tumor cells market strategic initiatives analysis
  • Fig. 17 Circulating tumor cells market: Technology movement analysis
  • Fig. 18 Circulating tumor cells market: Technology outlook and key takeaways
  • Fig. 19 CTC detection & enrichment methods market estimates and forecast, 2018 - 2030
  • Fig. 20 Immunocapture (label-based) estimates and forecast, 2018 - 2030
  • Fig. 21 Positive selection market estimates and forecast, 2018 - 2030
  • Fig. 22 Negative selection estimates and forecast, 2018 - 2030
  • Fig. 23 Size-based separation (label-free) market estimates and forecast, 2018 - 2030
  • Fig. 24 Membrane-based estimates and forecast, 2018 - 2030
  • Fig. 25 Microfluidic-based estimates and forecast, 2018 - 2030
  • Fig. 26 Density-based Separation (Label-free) estimates and forecast, 2018 - 2030
  • Fig. 27 Combined Methods estimates and forecast, 2018 - 2030
  • Fig. 28 CTC direct detection methods estimates and forecast, 2018 - 2030
  • Fig. 29 SERS estimates and forecast, 2018 - 2030
  • Fig. 30 Microscopy estimates and forecast, 2018 - 2030
  • Fig. 31 Others estimates and forecast, 2018 - 2030
  • Fig. 32 CTC Analysis estimates and forecast, 2018 - 2030
  • Fig. 33 Circulating tumor cells Market: Application movement Analysis
  • Fig. 34 Circulating tumor cells market: Application outlook and key takeaways
  • Fig. 35 Clinical/ Liquid Biopsy market estimates and forecasts, 2018 - 2030
  • Fig. 36 Risk Assessment market estimates and forecasts, 2018 - 2030
  • Fig. 37 Screening and Monitoring market estimates and forecasts, 2018 - 2030
  • Fig. 38 Research market estimates and forecasts, 2018 - 2030
  • Fig. 39 Cancer Stem Cell & Tumorogenesis Research market estimates and forecasts, 2018 - 2030
  • Fig. 40 Drug/Therapy Development market estimates and forecasts, 2018 - 2030
  • Fig. 41 Circulating tumor cells Market: Product movement Analysis
  • Fig. 42 Circulating tumor cells market: Product outlook and key takeaways
  • Fig. 43 Kits & reagents market estimates and forecasts, 2018 - 2030
  • Fig. 44 Blood collection tubes market estimates and forecasts, 2018 - 2030
  • Fig. 45 Devices or Systems market estimates and forecasts, 2018 - 2030
  • Fig. 46 Circulating tumor cells Market: Specimen movement Analysis
  • Fig. 47 Circulating tumor cells market: Specimen outlook and key takeaways
  • Fig. 48 Blood market estimates and forecasts, 2018 - 2030
  • Fig. 49 Bone marrow market estimates and forecasts, 2018 - 2030
  • Fig. 50 Other body fluids market estimates and forecasts, 2018 - 2030
  • Fig. 51 Circulating tumor cells Market: End-use movement Analysis
  • Fig. 52 Circulating tumor cells market: End-use outlook and key takeaways
  • Fig. 53 Research and academic institutes market estimates and forecasts, 2018 - 2030
  • Fig. 54 Hospital and clinics market estimates and forecasts, 2018 - 2030
  • Fig. 55 Diagnostic centers market estimates and forecasts, 2018 - 2030
  • Fig. 56 Global circulating tumor cells market: Regional movement analysis
  • Fig. 57 Global circulating tumor cells market: Regional outlook and key takeaways
  • Fig. 58 North America, by country
  • Fig. 59 North America
  • Fig. 60 North America market estimates and forecasts, 2018 - 2030
  • Fig. 61 U.S.
  • Fig. 62 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 63 Canada
  • Fig. 64 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 65 Europe
  • Fig. 66 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 67 UK
  • Fig. 68 UK market estimates and forecasts, 2018 - 2030
  • Fig. 69 Germany
  • Fig. 70 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 71 France
  • Fig. 72 France market estimates and forecasts, 2018 - 2030
  • Fig. 73 Italy
  • Fig. 74 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 75 Spain
  • Fig. 76 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 77 Denmark
  • Fig. 78 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 79 Sweden
  • Fig. 80 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 81 Norway
  • Fig. 82 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 83 Asia Pacific
  • Fig. 84 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 85 China
  • Fig. 86 China market estimates and forecasts, 2018 - 2030
  • Fig. 87 Japan
  • Fig. 88 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 89 India
  • Fig. 90 India market estimates and forecasts, 2018 - 2030
  • Fig. 91 Thailand
  • Fig. 92 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 93 South Korea
  • Fig. 94 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 95 Australia
  • Fig. 96 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 97 Latin America
  • Fig. 98 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 99 Brazil
  • Fig. 100 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 101 Mexico
  • Fig. 102 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 103 Argentina
  • Fig. 104 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 105 Middle East and Africa
  • Fig. 106 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 107 South Africa
  • Fig. 108 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 109 Saudi Arabia
  • Fig. 110 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 111 UAE
  • Fig. 112 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 113 Kuwait
  • Fig. 114 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 115 Market position of key market players - Circulating tumor cells market
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!